MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s40560-026-00906-2

Медицинская библиотека · Journal of intensive care · 2026

Association of esketamine exposure with secondary sclerosing cholangitis in critically ill patients: a retrospective cohort analysis of 20,000 ICU cases.

Zeiner Sebastian, Rettenbacher Julian, Nowak Nikolaus Michael, Duma Andreas, Schaden Eva, Hammerle Fabian Peter, Laxar Daniel, Adelmann Dieter, Müller Johannes, Wohlrab Peter, Kimberger Oliver

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Secondary sclerosing cholangitis in critically ill patients (SSC-CIP) is a severe cholangiopathy with high mortality observed in ICU survivors. While prolonged mechanical ventilation and COVID-19-associated acute respiratory distress syndrome (ARDS) are established risk factors, the impact of ketamine, a commonly used sedative, remains controversial.

METHODS

This retrospective study included 20,973 ICU patients admitted between January 2014 and February 2022 at a tertiary university hospital. Patients with severe cholestasis were preselected (n = 532) and reviewed for SSC-CIP diagnosis or likelihood of SSC-CIP. Multivariate logistic regression was used to evaluate Esketamine exposure and dose dependency while controlling for other risk factors.

RESULTS

SSC-CIP was confirmed in 0.11% of patients; 0.20% had clinical profiles compatible with undiagnosed SSC-CIP. Among COVID-19 ICU patients, the incidence was 3.24%. Esketamine administration was significantly associated with SSC-CIP (70% of SSC cases vs. 7% controls). In a multivariate analysis, cumulative Esketamine dose (OR 1.021 per gram), ICU duration (OR 1.031/day), and COVID-19 status (OR 20.6) were independent predictors.

CONCLUSION

Esketamine exposure was associated with SSC-CIP in a dose-dependent manner, highlighting the need for judicious sedative use in critically ill patients. Our cholestasis-first screening strategy also demonstrates a novel approach for detecting previously unrecognized SSC-CIP cases. Future prospective trials should evaluate the benefits of ketamine-free sedation strategies in high-risk populations.

Для цитирования: Zeiner Sebastian, Rettenbacher Julian, Nowak Nikolaus Michael, Duma Andreas, Schaden Eva, Hammerle Fabian Peter, Laxar Daniel, Adelmann Dieter, Müller Johannes, Wohlrab Peter, Kimberger Oliver. Association of esketamine exposure with secondary sclerosing cholangitis in critically ill patients: a retrospective cohort analysis of 20,000 ICU cases.. Journal of intensive care. 2026. DOI: 10.1186/s40560-026-00906-2.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.